Developer docs
API playgroundTry for free, no card

Search company profiles

Inductive Bio

Full company profile

uuid00009is

Namestring
Inductive Bio
Legal namestring
Inductive Bio, Inc.
Websiteurl
inductive.bio
Company typeenum
Private
Founded yearint
2023
Descriptiontext

Inductive Bio is a New York-based, venture-backed AI/ML company founded in 2023 that builds a virtual chemistry lab platform for small-molecule drug discovery. Its product suite is anchored by Compass (the virtual lab interface), Beacon-1 (a class of ADMET prediction models trained on a pre-competitive industry consortium and fine-tuned to each customer's chemical space), Indy (an AI chemistry assistant that automates assay QC, SAR analysis, and analog enumeration), and Digital Organs (toxicity models trained on billions of drug-organ interaction data points). Layered on top are three service offerings: Embedded Experts (where Inductive's chemists and DMPK scientists operate the virtual lab alongside partner teams), ADME-One™ (a co-developed Tier 1 ADME + human PK projection platform with Ginkgo Bioworks Datapoints and Tangible Scientific, priced several times lower than industry standard), and End-to-End Chemistry (AI-informed synthesis and testing through CRO partners including Enamine, Ginkgo, and Tangible Scientific).

The company sells primarily through a direct enterprise sales motion targeting biopharma R&D teams, with "Book a Demo" CTAs gating quote-based Compass subscriptions, Embedded Experts engagements, and ADME-One services; revenue is supplemented by a non-dilutive ARPA-H grant (up to $21M). Customers include venture-backed biotechs (Rapport Therapeutics, Nested Therapeutics, Arrakis Therapeutics, Belharra Therapeutics, Aleksia Therapeutics, Nexo Therapeutics, Architect Therapeutics, Tenvie) and enterprise biopharma (Denali Therapeutics, Amgen). The company is independently validated by first-place finishes in consecutive open-world ADMET blind competitions (Polaris 2025, OpenADMET 2026 with ExpansionRx), SOC 2 compliance, and partnerships including CAS Connections and the ARPA-H CATALYST DATALMAP project.

Short descriptiontext

Inductive Bio builds an AI/ML virtual chemistry lab platform for small-molecule drug discovery, offering ADMET prediction models (Beacon-1), a virtual lab interface (Compass), an AI chemistry assistant (Indy), and integrated lab services (ADME-One) to biopharma R&D teams.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug discovery, ADMET prediction, small molecule optimization, virtual chemistry lab, pharmacokinetic modeling
Industry2 codes
PRIMARYHLAGAHAG
Impurity / Reference Standard Synthesis & Characterization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Analytical Laboratory Instrument Manufacturing334516
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
AI-Driven Drug Discovery Software
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model5 records
1Compass Platform Subscriptions
TypeSubscription Recurring
Description

Recurring software subscription revenue from the Compass virtual lab platform, which provides direct access to run virtual experiments, review predictions in real time, and decide what to synthesize. The platform is used by biopharma partners to optimize active small-molecule programs.

inductive.bio
2Embedded Experts Professional Services
TypeProfessional Services
Description

Fee-based professional services where Inductive's chemistry, computational chemistry, and DMPK experts operate as an extension of the customer's team, running experiments and delivering curated compound ideas tailored to design strategy. Acts as AI-powered drug discovery consultants.

inductive.bio
3ADME-One Tier 1 ADME Service
TypeManaged Services
Description

Integrated ADME service offering priced several times lower than the industry standard, combining high-throughput Tier 1 ADME assays with AI-driven human PK projection. Delivered via the Ginkgo Bioworks Datapoints and Tangible Scientific partnership. Returns results in days rather than weeks.

inductive.bio
4Government Grant Funding (ARPA-H)
TypeSubscription Recurring
Description

Non-dilutive government funding from the Advanced Research Projects Agency for Health (ARPA-H) CATALYST program. Up to $21M award to lead the DATAMAP project developing AI drug toxicity models. This supplements commercial revenue with grant-based research funding.

inductive.bio
5End-to-End Chemistry CRO Services
TypeManaged Services
Description

Service revenue from end-to-end program acceleration through partnerships with select CROs (Enamine, Ginkgo Bioworks, Tangible Scientific), providing AI-informed synthesis and testing in a tight feedback loop with the virtual lab.

inductive.bio
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Quote-based enterprise pricing via "Book a Demo"
ModelOtherBilling cadenceAnnual
Notes

Pricing is not publicly disclosed. Customers must request a demo to receive pricing information. The Compass platform, Beacon-1 models, Indy, Embedded Experts, ADME-One, and End-to-End Chemistry services all use quote-based pricing.

inductive.bio
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 6 records shown
1Compass
Description

Compass is Inductive Bio's virtual lab software interface that allows drug discovery teams to run virtual experiments, review predictions in real time, and decide what compounds to synthesize; it is the interface to Inductive's ADMET and PK models.

inductive.bio
+5 more records
Core offering1 text field

Inductive Bio provides an AI/ML-powered virtual lab platform for small molecule drug discovery. Its Compass software, Beacon-1 ADMET prediction models, and Indy AI chemistry assistant enable biopharma teams to run millions of in silico experiments, predict ADMET properties, and prioritize compounds for synthesis. Layered on top are Embedded Experts professional services, the ADME-One integrated ADME platform (co-developed with Ginkgo Bioworks Datapoints and Tangible Scientific), and End-to-End Chemistry services delivered via select CRO partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • Consecutive 1st place finishes in the world's largest ADMET benchmarks (Polaris 2025, OpenADMET-ExpansionRx 2026)
+7 more records
Product overview1 text field

Inductive Bio operates a unified virtual chemistry lab platform composed of multiple integrated products. The Compass platform serves as the core interface (virtual lab bench) that gives teams direct access to run virtual experiments, review predictions, and decide what to synthesize in real time. Compass is powered by Beacon-1 (the gold-standard ADMET model class trained on a pre-competitive consortium data) and is assisted by Indy (an AI chemistry assistant that automates QC, data mining, and rational analog enumeration). The pre-competitive Data Consortium supplies the diverse ADMET data foundation used to train and fine-tune Beacon-1. Digital organs are a parallel product capability trained on billions of drug-organ interaction data points to predict safety in humans. Three service offerings layer on top of the software: Embedded Experts (dedicated medicinal chemistry, computational chemistry, and DMPK support from Inductive's scientists operating the virtual lab alongside partners); ADME-One™ (a fully integrated Tier 1 ADME + human PK projection platform co-developed with Ginkgo Datapoints and Tangible Scientific); and End-to-End Chemistry (AI-informed synthesis and testing via select CRO partners to close the loop between virtual and wet lab). The architecture is platform-plus-modules, with Compass as the central user-facing product and Beacon-1, Indy, the Consortium, Digital organs, and the three service lines as its integrated modules and offerings.

Product and service1 record
1Compass
Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-06-03
Description

Technology integration as part of the CAS Connections framework. CAS launched CAS Connections, an integration framework that embeds its scientific knowledge collection and CAS Newton agentic AI into existing R&D workflow platforms, with Inductive Bio as one of the first wave of collaborators. The framework supports deployment via APIs, Model Context Protocol, and AI platform integrations for tools such as Anthropic's Claude and Microsoft Copilot.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-08
Description

Collaborating on the DATAMAP project (Digital Acceleration of Toxicity Assessment with Mechanistic and AI-driven Predictions) under the ARPA-H CATALYST program. Amgen advises on development, real-world context of use in drug development, and potential applications to novel therapies. Amgen plans to submit an investigational new drug application (IND) to the FDA using the technology developed in the project.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-08
Description

Research collaborator on the DATAMAP project under the ARPA-H CATALYST program. The institution participates in a $21M federal project called CATALYST to enhance drug safety testing using human organoids and AI. Involved in developing more accurate models for predicting drug toxicity and reducing animal testing.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-08
Description

Research collaborator on the DATAMAP project under the ARPA-H CATALYST program. Part of a multi-institution collaboration to generate biological data from organoids, ex-vivo human tissue, and microphysiological systems for AI model training.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-08
Description

Torch Bio is a University of Michigan Medical School spinout company that collaborates on the DATAMAP project under the ARPA-H CATALYST program. Involved in generating biological data from advanced human model systems for AI toxicity model development.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-08-20
Description

Strategic partnership to deploy AI-driven lab-in-the-loop drug discovery workflows across the biopharma industry. Combines Ginkgo Datapoints' rapid ADME profiling with Inductive Bio's model-driven chemistry design platform. In May 2026, the partnership was deepened with the co-development and launch of ADME-One™, a fully integrated ADME platform. Ginkgo Datapoints handles all five Tier 1 ADME assays in its automated Boston laboratory.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-08-20
Description

Strategic partnership to deploy AI-driven lab-in-the-loop drug discovery. Tangible Scientific's API-enabled compound management platform handles compound intake, plating, real-time tracking, and management for ADME-One orders. Co-develops the ADME-One platform with Ginkgo Bioworks Datapoints and Inductive Bio. Based in Natick, MA with same-day courier service to Boston-area partners.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-12-13
Description

One of Inductive Bio's initial industry partners established when the company emerged from stealth in December 2023. Collaborating on the ML platform to speed up compound optimization by improving ADMET property predictions.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

End-to-End Chemistry partner. Inductive partners with Enamine and other select drug discovery CROs to help rapidly test best ideas. Compounds move from AI-powered predictions in the virtual lab to traditional synthetic chemistry and high-throughput DMPK assays at Enamine.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic research collaboration. Co-developed a probabilistic human dose projection case study that built a framework translating preclinical data into predicted human dose distributions while explicitly propagating uncertainty. The case study triaged three advanced candidates during late lead optimization, producing a clear ranking that the leaderboard couldn't. Co-authors Amy Hart and Eunice Park from Aleksia collaborated with Gaby Gerlach and Nic Pabon from Inductive Bio.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Public computational chemistry and molecular simulation platform with broad pharma/biotech adoption. Directly comparable in offering ADMET prediction, virtual screening, and physics-based drug discovery software to biopharma, with a much larger platform and established enterprise customer base.

TypeBroad incumbent
Description

Public AI-driven drug discovery company combining high-throughput biology, chemistry, and ML for small molecule and target identification. Comparable in targeting biopharma customers with AI-enabled discovery workflows, but operates at significantly larger scale with internal wet lab infrastructure.

TypeDirect peer
Description

Clinical-stage AI drug discovery company with end-to-end platform spanning target identification through clinical development. Directly comparable in offering AI/ML-driven small molecule drug discovery services to biopharma, with similar target customer base and business model.

4Isomorphic Labs
TypeBroad incumbent
Description

Alphabet-owned AI drug discovery spinout of DeepMind. Comparable in applying state-of-the-art ML to small molecule discovery and protein structure prediction, with massive capital backing and pharma partnerships (Eli Lilly, Novartis).

TypeDirect peer
Description

AI-driven precision medicine company with end-to-end drug discovery platform and clinical-stage assets. Directly comparable in offering AI-based small molecule design and ADMET optimization services to biopharma partners, though recently restructured and focused on oncology.

TypeDirect peer
Description

AI-driven small molecule drug discovery company using structure-based AtomNet platform for hit identification and lead optimization. Comparable in serving biopharma with AI/ML-powered compound design, with similar technology focus and customer profile.

TypeDirect peer
Description

AI-driven small molecule discovery company combining wet lab data generation with ML models. Directly comparable in using proprietary experimental data to train foundation models for chemistry, and Edward Williams previously worked there before joining Inductive Bio.

8Iambic Therapeutics
TypeDirect peer
Description

AI-driven drug discovery company developing clinical and preclinical small molecule candidates. Directly comparable in using ML/AI for small molecule design with platform technology serving biopharma, and competes in similar ADMET and lead optimization space.

TypeEmerging player
Description

AI/ML-driven antibody design platform with wet lab integration for ML-guided design cycles. Comparable in applying ML to drug discovery with lab-in-the-loop methodology, founded by Mark DePristo who serves on Inductive Bio's advisory board, and uses similar integration of AI with experimental chemistry.

TypeDirect peer
Description

AI-driven drug discovery company combining quantum physics, AI, and robotics for small molecule R&D. Comparable in offering AI-powered drug discovery services to biopharma with significant CRO/scale-up capabilities and a similar model of integrated AI + wet lab workflow.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat7 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI capability12 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Inductive Bio

AI-Driven Drug Discovery Softwareinductive.bio

Inductive Bio builds an AI/ML virtual chemistry lab platform for small-molecule drug discovery, offering ADMET prediction models (Beacon-1), a virtual lab interface (Compass), an AI chemistry assistant (Indy), and integrated lab services (ADME-One) to biopharma R&D teams.

What Inductive Bio does

Inductive Bio is a New York-based, venture-backed AI/ML company founded in 2023 that builds a virtual chemistry lab platform for small-molecule drug discovery. Its product suite is anchored by Compass (the virtual lab interface), Beacon-1 (a class of ADMET prediction models trained on a pre-competitive industry consortium and fine-tuned to each customer's chemical space), Indy (an AI chemistry assistant that automates assay QC, SAR analysis, and analog enumeration), and Digital Organs (toxicity models trained on billions of drug-organ interaction data points). Layered on top are three service offerings: Embedded Experts (where Inductive's chemists and DMPK scientists operate the virtual lab alongside partner teams), ADME-One™ (a co-developed Tier 1 ADME + human PK projection platform with Ginkgo Bioworks Datapoints and Tangible Scientific, priced several times lower than industry standard), and End-to-End Chemistry (AI-informed synthesis and testing through CRO partners including Enamine, Ginkgo, and Tangible Scientific).

The company sells primarily through a direct enterprise sales motion targeting biopharma R&D teams, with "Book a Demo" CTAs gating quote-based Compass subscriptions, Embedded Experts engagements, and ADME-One services; revenue is supplemented by a non-dilutive ARPA-H grant (up to $21M). Customers include venture-backed biotechs (Rapport Therapeutics, Nested Therapeutics, Arrakis Therapeutics, Belharra Therapeutics, Aleksia Therapeutics, Nexo Therapeutics, Architect Therapeutics, Tenvie) and enterprise biopharma (Denali Therapeutics, Amgen). The company is independently validated by first-place finishes in consecutive open-world ADMET blind competitions (Polaris 2025, OpenADMET 2026 with ExpansionRx), SOC 2 compliance, and partnerships including CAS Connections and the ARPA-H CATALYST DATALMAP project.

Inductive Bio firmographics

Firmographics
Name
Inductive Bio
Legal name
Inductive Bio, Inc.
Website
https://inductive.bio
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
11–50 employees
Short description
Inductive Bio builds an AI/ML virtual chemistry lab platform for small-molecule drug discovery, offering ADMET prediction models (Beacon-1), a virtual lab interface (Compass), an AI chemistry assistant (Indy), and integrated lab services (ADME-One) to biopharma R&D teams.
Ownership category
akta.pro rank

Inductive Bio industry classification

Industry
Product category
AI-Driven Drug Discovery Software
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Analytical Laboratory Instrument Manufacturing (334516)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAHAG
Impurity / Reference Standard Synthesis & Characterization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • AI drug discovery
  • ADMET prediction
  • Small molecule optimization
  • Virtual chemistry lab
  • Pharmacokinetic modeling

Where Inductive Bio is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Inductive Bio business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Compass Platform Subscriptions: Recurring software subscription revenue from the Compass virtual lab platform, which provides direct access to run virtual experiments, review predictions in real time, and decide what to synthesize. The platform is used by biopharma partners to optimize active small-molecule programs.
  2. Embedded Experts Professional Services: Fee-based professional services where Inductive's chemistry, computational chemistry, and DMPK experts operate as an extension of the customer's team, running experiments and delivering curated compound ideas tailored to design strategy. Acts as AI-powered drug discovery consultants.
  3. ADME-One Tier 1 ADME Service: Integrated ADME service offering priced several times lower than the industry standard, combining high-throughput Tier 1 ADME assays with AI-driven human PK projection. Delivered via the Ginkgo Bioworks Datapoints and Tangible Scientific partnership. Returns results in days rather than weeks.
  4. Government Grant Funding (ARPA-H): Non-dilutive government funding from the Advanced Research Projects Agency for Health (ARPA-H) CATALYST program. Up to $21M award to lead the DATAMAP project developing AI drug toxicity models. This supplements commercial revenue with grant-based research funding.
  5. End-to-End Chemistry CRO Services: Service revenue from end-to-end program acceleration through partnerships with select CROs (Enamine, Ginkgo Bioworks, Tangible Scientific), providing AI-informed synthesis and testing in a tight feedback loop with the virtual lab.

Pricing tiers

ModelBillingPrice
OtherAnnualQuote-based enterprise pricing via "Book a Demo"

Go-to-market motion4 records

Distribution channels5 records

Marketing channels8 records

Inductive Bio product offering

Product offering

Core offering

Inductive Bio provides an AI/ML-powered virtual lab platform for small molecule drug discovery. Its Compass software, Beacon-1 ADMET prediction models, and Indy AI chemistry assistant enable biopharma teams to run millions of in silico experiments, predict ADMET properties, and prioritize compounds for synthesis. Layered on top are Embedded Experts professional services, the ADME-One integrated ADME platform (co-developed with Ginkgo Bioworks Datapoints and Tangible Scientific), and End-to-End Chemistry services delivered via select CRO partners.

Product overview

Inductive Bio operates a unified virtual chemistry lab platform composed of multiple integrated products. The Compass platform serves as the core interface (virtual lab bench) that gives teams direct access to run virtual experiments, review predictions, and decide what to synthesize in real time. Compass is powered by Beacon-1 (the gold-standard ADMET model class trained on a pre-competitive consortium data) and is assisted by Indy (an AI chemistry assistant that automates QC, data mining, and rational analog enumeration). The pre-competitive Data Consortium supplies the diverse ADMET data foundation used to train and fine-tune Beacon-1. Digital organs are a parallel product capability trained on billions of drug-organ interaction data points to predict safety in humans. Three service offerings layer on top of the software: Embedded Experts (dedicated medicinal chemistry, computational chemistry, and DMPK support from Inductive's scientists operating the virtual lab alongside partners); ADME-One™ (a fully integrated Tier 1 ADME + human PK projection platform co-developed with Ginkgo Datapoints and Tangible Scientific); and End-to-End Chemistry (AI-informed synthesis and testing via select CRO partners to close the loop between virtual and wet lab). The architecture is platform-plus-modules, with Compass as the central user-facing product and Beacon-1, Indy, the Consortium, Digital organs, and the three service lines as its integrated modules and offerings.

Differentiator

Problem solved

Functional benefit

Brands

  • Compass: Compass is Inductive Bio's virtual lab software interface that allows drug discovery teams to run virtual experiments, review predictions in real time, and decide what compounds to synthesize; it is the interface to Inductive's ADMET and PK models.
  • Beacon-1
  • Indy
  • ADME-One™
  • Consortium
  • Embedded Experts

Products and services

  • Compass

Quantifiable outcome

  • Consecutive 1st place finishes in the world's largest ADMET benchmarks (Polaris 2025, OpenADMET-ExpansionRx 2026)
  • +7 more outcomes

Companies that use Inductive Bio

Customer profile

Named customers10 records

Segments2 records

Ideal customer profiles2 records

Inductive Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability12 records

Feature7 records

Inductive Bio partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core and flagship.

  • CAS (American Chemical Society)coreTechnology or Integration · 3 June 2026Technology integration as part of the CAS Connections framework. CAS launched CAS Connections, an integration framework that embeds its scientific knowledge collection and CAS Newton agentic AI into existing R&D workflow platforms, with Inductive Bio as one of the first wave of collaborators. The framework supports deployment via APIs, Model Context Protocol, and AI platform integrations for tools such as Anthropic's Claude and Microsoft Copilot.
  • AmgencoreStrategic or Co-development Partner · 8 December 2025Collaborating on the DATAMAP project (Digital Acceleration of Toxicity Assessment with Mechanistic and AI-driven Predictions) under the ARPA-H CATALYST program. Amgen advises on development, real-world context of use in drug development, and potential applications to novel therapies. Amgen plans to submit an investigational new drug application (IND) to the FDA using the technology developed in the project.
  • Cincinnati Children's Hospital Medical CentercoreStrategic or Co-development Partner · 8 December 2025Research collaborator on the DATAMAP project under the ARPA-H CATALYST program. The institution participates in a $21M federal project called CATALYST to enhance drug safety testing using human organoids and AI. Involved in developing more accurate models for predicting drug toxicity and reducing animal testing.
  • Baylor College of MedicinecoreStrategic or Co-development Partner · 8 December 2025Research collaborator on the DATAMAP project under the ARPA-H CATALYST program. Part of a multi-institution collaboration to generate biological data from organoids, ex-vivo human tissue, and microphysiological systems for AI model training.
  • Torch BiocoreStrategic or Co-development Partner · 8 December 2025Torch Bio is a University of Michigan Medical School spinout company that collaborates on the DATAMAP project under the ARPA-H CATALYST program. Involved in generating biological data from advanced human model systems for AI toxicity model development.
  • Ginkgo Bioworks (Datapoints)flagshipStrategic or Co-development Partner · 20 August 2025Strategic partnership to deploy AI-driven lab-in-the-loop drug discovery workflows across the biopharma industry. Combines Ginkgo Datapoints' rapid ADME profiling with Inductive Bio's model-driven chemistry design platform. In May 2026, the partnership was deepened with the co-development and launch of ADME-One™, a fully integrated ADME platform. Ginkgo Datapoints handles all five Tier 1 ADME assays in its automated Boston laboratory.
  • Tangible ScientificflagshipStrategic or Co-development Partner · 20 August 2025Strategic partnership to deploy AI-driven lab-in-the-loop drug discovery. Tangible Scientific's API-enabled compound management platform handles compound intake, plating, real-time tracking, and management for ADME-One orders. Co-develops the ADME-One platform with Ginkgo Bioworks Datapoints and Inductive Bio. Based in Natick, MA with same-day courier service to Boston-area partners.
  • Denali TherapeuticscoreStrategic or Co-development Partner · 13 December 2023One of Inductive Bio's initial industry partners established when the company emerged from stealth in December 2023. Collaborating on the ML platform to speed up compound optimization by improving ADMET property predictions.
  • EnaminecoreChannel Partner/ Reseller/ DistributorEnd-to-End Chemistry partner. Inductive partners with Enamine and other select drug discovery CROs to help rapidly test best ideas. Compounds move from AI-powered predictions in the virtual lab to traditional synthetic chemistry and high-throughput DMPK assays at Enamine.
  • Aleksia TherapeuticscoreStrategic or Co-development PartnerStrategic research collaboration. Co-developed a probabilistic human dose projection case study that built a framework translating preclinical data into predicted human dose distributions while explicitly propagating uncertainty. The case study triaged three advanced candidates during late lead optimization, producing a clear ranking that the leaderboard couldn't. Co-authors Amy Hart and Eunice Park from Aleksia collaborated with Gaby Gerlach and Nic Pabon from Inductive Bio.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Inductive Bio competitors and assessment

Company assessment

Broad incumbents

  • Schrödinger: Public computational chemistry and molecular simulation platform with broad pharma/biotech adoption. Directly comparable in offering ADMET prediction, virtual screening, and physics-based drug discovery software to biopharma, with a much larger platform and established enterprise customer base.
  • Recursion Pharmaceuticals: Public AI-driven drug discovery company combining high-throughput biology, chemistry, and ML for small molecule and target identification. Comparable in targeting biopharma customers with AI-enabled discovery workflows, but operates at significantly larger scale with internal wet lab infrastructure.
  • Isomorphic Labs: Alphabet-owned AI drug discovery spinout of DeepMind. Comparable in applying state-of-the-art ML to small molecule discovery and protein structure prediction, with massive capital backing and pharma partnerships (Eli Lilly, Novartis).

Direct peers

  • Insilico Medicine: Clinical-stage AI drug discovery company with end-to-end platform spanning target identification through clinical development. Directly comparable in offering AI/ML-driven small molecule drug discovery services to biopharma, with similar target customer base and business model.
  • Exscientia: AI-driven precision medicine company with end-to-end drug discovery platform and clinical-stage assets. Directly comparable in offering AI-based small molecule design and ADMET optimization services to biopharma partners, though recently restructured and focused on oncology.
  • Atomwise: AI-driven small molecule drug discovery company using structure-based AtomNet platform for hit identification and lead optimization. Comparable in serving biopharma with AI/ML-powered compound design, with similar technology focus and customer profile.
  • Terray Therapeutics: AI-driven small molecule discovery company combining wet lab data generation with ML models. Directly comparable in using proprietary experimental data to train foundation models for chemistry, and Edward Williams previously worked there before joining Inductive Bio.
  • Iambic Therapeutics: AI-driven drug discovery company developing clinical and preclinical small molecule candidates. Directly comparable in using ML/AI for small molecule design with platform technology serving biopharma, and competes in similar ADMET and lead optimization space.
  • XtalPi: AI-driven drug discovery company combining quantum physics, AI, and robotics for small molecule R&D. Comparable in offering AI-powered drug discovery services to biopharma with significant CRO/scale-up capabilities and a similar model of integrated AI + wet lab workflow.

Emerging players

  • BigHat Biosciences: AI/ML-driven antibody design platform with wet lab integration for ML-guided design cycles. Comparable in applying ML to drug discovery with lab-in-the-loop methodology, founded by Mark DePristo who serves on Inductive Bio's advisory board, and uses similar integration of AI with experimental chemistry.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

Inductive Bio social profiles

Digital presence

Inductive Bio compliance and trust

Trust signal

Compliance1 record

Inductive Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Inductive Bio leadership team

Management profile

Number of profiles

Profiles11 records

Inductive Bio funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Inductive Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Inductive Bio

What does Inductive Bio do?

Inductive Bio provides an AI/ML-powered virtual lab platform for small molecule drug discovery. Its Compass software, Beacon-1 ADMET prediction models, and Indy AI chemistry assistant enable biopharma teams to run millions of in silico experiments, predict ADMET properties, and prioritize compounds for synthesis. Layered on top are Embedded Experts professional services, the ADME-One integrated ADME platform (co-developed with Ginkgo Bioworks Datapoints and Tangible Scientific), and End-to-End Chemistry services delivered via select CRO partners.

Is Inductive Bio a public or private company?

Inductive Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Inductive Bio founded?

Inductive Bio was founded in 2023. It employs 11 to 50 people.

Where is Inductive Bio based?

Inductive Bio is headquartered in San Francisco, United States, in the North America region.

How does Inductive Bio make money?

Five revenue lines are on record. Compass Platform Subscriptions are the primary driver. The others are embedded Experts Professional Services, ADME-One Tier 1 ADME Service, government Grant Funding (ARPA-H) and end-to-End Chemistry CRO Services.

Who are Inductive Bio's main competitors?

Broad incumbents on record are Schrödinger, Recursion Pharmaceuticals and Isomorphic Labs. Direct peers are Insilico Medicine, Exscientia, Atomwise, Terray Therapeutics, Iambic Therapeutics and XtalPi. BigHat Biosciences is listed as an emerging player.

Does Inductive Bio have an API?

Yes. Inductive Bio's Compass models are integrated seamlessly into the tools partners already use via API, enabling access to run virtual experiments, review predictions, and decide what to synthesize in real time. The web application is accessible at app.inductive.bio/login. The CAS Connections integration framework (which embeds CAS scientific content and CAS Newton agentic AI into Inductive Bio's R&D platform) supports deployment via APIs, Model Context Protocol (MCP), and AI platform integrations.

What industry is Inductive Bio in?

Inductive Bio's product category is AI-Driven Drug Discovery Software. Its primary akta.pro industry code is HLAGAHAG, Impurity / Reference Standard Synthesis & Characterization, with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireInductive Places First in OpenADMET CYP Inhibition Challenge, Its Fourth Consecutive AI Drug Discovery Benchmark WinInductive placed first in the OpenADMET CYP Direct Inhibition Blind Challenge, beating over 270 participants from NVIDIA, Recursion, and others. Its Beacon models predicted pIC50 for 750 compounds across four CYP isoforms, marking its fourth consecutive first-place finish in OpenADMET benchmarks.AdvfnInductive Launches Beacon-2, Making Human Dose Computable for Chemists and AI Agents Across BiopharmaInductive launched Beacon-2, a system that predicts a small molecule's human dose from its chemical structure. The system's ADMET models won three consecutive OpenADMET blind challenges, beating over 750 competitors. It is available to partners through Compass, where it is already running on live drug discovery programs.PR NewswireInductive Launches Beacon-2, Making Human Dose Computable for Chemists and AI Agents Across BiopharmaInductive launched Beacon-2, a system that predicts the efficacious human dose of small molecules from their chemical structure. The system's ADMET models won three consecutive OpenADMET blind challenges, beating over 750 competitors. It is available through Compass, where it is already running on live drug discovery programs.PR NewswireInductive Bio launches Indy, an AI chemistry assistant, to double the capacity of every medicinal chemistInductive Bio launched Indy, an AI chemistry assistant, available to partners. In head-to-head benchmarks, Indy achieved 89% accuracy on dose-response curves, outperforming Claude Opus 5 and GPT-5.6 Sol. The assistant aims to double medicinal chemists' productivity.PR NewswireInductive Bio Wins 3rd Consecutive AI Drug Discovery BenchmarkInductive Bio placed first in OpenADMET's PXR Blind Challenge, beating over 350 competitors. The company secured its third consecutive win in AI drug-discovery benchmarks, including the ASAP-Polaris-OpenADMET Antiviral and ExpansionRx-OpenADMET challenges. The win supports its broader drug safety focus, including an ARPA-H award for liver injury and cardiotoxicity models.STATDrug metabolism AI competition results show that bigger may not always be better | STATThe results of an AI competition focused on drug metabolism prediction show that better data may be more important than larger models in predicting whether drug candidates will activate the PXR receptor, a key sensor that regulates enzyme production for breaking down approximately 50% of all marketed drugs. Inductive Bio won the competition, though a 28-way statistical tie among participants indicates that model scale alone does not determine predictive accuracy. The findings highlight a broader shift in the pharmaceutical industry as drug developers increasingly seek AI tools that can identify problematic drug candidates earlier in the development process.AijournInductive Bio joins Anthropic’s Connector Ecosystem for Life Sciences, Surfacing State-of-the-Art ADMET Prediction to Drug Discovery Scientists through ClaudeInductive Bio announced it has joined Anthropic's life sciences connector ecosystem and launched a Model Context Protocol (MCP) connector that makes its ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) prediction models accessible directly within Claude, Anthropic's AI assistant. The integration allows any drug discovery scientist using Claude to access state-of-the-art ADMET predictions and reason about drug properties for chemical structures in natural language within their existing workflow. Inductive Bio's models were independently validated as state-of-the-art, having placed first among more than 370 entries from large pharma and AI companies in the OpenADMET-ExpansionRx blind challenge, and the company emphasizes that submitted chemical structures are not retained or used to train their models.PR NewswireInductive Bio joins Anthropic's Connector Ecosystem for Life Sciences, Surfacing State-of-the-Art ADMET Prediction to Drug Discovery Scientists through ClaudeInductive Bio announced it has joined Anthropic's life sciences ecosystem and launched an MCP connector that makes its ADMET (Absorption, Distribution, Metabolism, Excretion, & Toxicity) prediction models accessible directly within Claude for drug discovery scientists. The integration allows any scientist to explore chemical structures, receive ADMET property predictions, and reason about those predictions alongside their compound design rationale using natural language. Inductive Bio's models, which placed first among over 370 entries from large pharma and AI companies in the OpenADMET-ExpansionRx blind challenge, are now available on-demand through Claude and Claude Science without retaining submitted chemical structures for model training.HpcwireSince 1987 – Covering the Fastest Computers in the World and the People Who Run ThemCAS, a division of the American Chemical Society, announced on June 3, 2026 the launch of CAS Connections, an integration framework that embeds its scientific Content Collection and CAS Newton AI directly into R&D platforms used by researchers. Initial platform partners include Albert Invent, Sapio Sciences, Inductive Bio, Scilligence, and Wolfram Research, which will integrate CAS-curated scientific knowledge and conversational AI capabilities into their existing tools. The framework supports deployment via API, Model Context Protocol, and integrations with AI platforms such as Anthropic's Claude and Microsoft Copilot, enabling researchers to access verified scientific data without leaving their research environment.PR Newswire APACCAS Connections brings trusted scientific data and AI to leading R&D platformsCAS announced CAS Connections, an integration framework embedding its scientific data and CAS Newton agentic AI into R&D tools. Initial collaborations include Albert Invent, Sapio Sciences, Inductive Bio, Scilligence, and Wolfram Research. Additional integrations will be announced throughout the year.